- published: 06 Apr 2016
- views: 318
Professor Sir Michael Rawlins FMedSci is the chair of the Medicines and Healthcare Products Regulatory Agency. He took up post formally from 1 December 2014 and his appointment will be for three years. He is also currently Chairman of UK Biobank.
He is an Honorary Professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne.
He was Chair of the National Institute for Health and Care Excellence (NICE) from 1999 to 2013. He was President of the Royal Society of Medicine from 2012 to 2014.
Rawlins obtained his undergraduate medical degree at St Thomas' Hospital, graduating in 1965. His post-graduate training in clinical pharmacology and general medicine was completed at St Thomas' and the Hammersmith hospitals, with a year at the Karolinska Institute in Stockholm.
From 1973 to 2006, Rawlins was the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at Newcastle University where he undertook research into the safety and efficacy of new and established pharmacological treatments. At the same time he was consultant physician to the Newcastle University Hospitals where he practised clinical pharmacology and general internal medicine.
Professor Sir Michael Rawlins interview, Chair UK Medicines & Healthcare Products Regulatory Agency
Honorary Degree Recipient: Professor Sir Michael Rawlins
[HTAi Seoul 2013] Keynote Lecture - Sir Michael RAWLINS
MICHAEL RAWLINS
Michael Rawlins - Saints or Sinners - what is the role of the pharmaceutical industry?
Health Reform and the Economy (Michael Rawlins)
Opening remarks - Professor Sir Michael Rawlins, Chairman, UK Biobank Board
Sir Michael Rawlins Prince Mahidol Award speech
Sir Michael Rawlins on Comparative Effectiveness in the U.K
Sir Michael Rawlins, Chairman of NICE, speaks at BIO 2010
We realise that there are a lot of different views about whether there is a need to change how pharmaceutical companies interact with healthcare professionals (HCPs) and if so how this should happen. We have made a number of changes to how we interact with HCPs, across sales representative incentives, medical education and payments to HCPs to speak on our behalf. We’ve made these changes because we believe the established way of operating is outdated and doesn’t works effectively for patients, HCPs or the pharmaceutical industry. Professor Sir Michael Rawlins is the chair of the UK Medicines and Healthcare Products Regulatory Agency as well as chairman of Biobank. Prior to this he was Chair of the UK National Institute for Health and Care Excellence (NICE) from 1999 to 2013. In this vide...
University of the Sciences 2010 Commencement, May 26, 2010, The Mann Center for the Performing Arts
Evidence, Values and Decision-Making Sir Michael RAWLINS, President, Royal Society of Medicine, UK
Visit USC on YouTube: http://www.youtube.com/usc Learn more about the University of Southern California: http://www.usc.edu The USC Schaeffer Center for Health Policy and Economics hosted a conference Oct. 22, 2010, titled, "Health Reform and the Economy: Are They Good for Each Other?" At this conference, Sir Michael Rawlins, chairman of the National Institute of Health and Clinical Excellence (NICE) in the U.K., brought an international perspective by describing how his organization sets governmental coverage policy and prices for drugs and treatments. He emphasized the role of science in setting benchmarks but also acknowledged that NICE factors in social value judgments, particularly for controversial treatments. The conference also included panels examining critical reform issues re...
Sir Michael Rawlins, chairman of the U.K.'s Institute for Health and Clinical Excellence (NICE), observes that NICE has "increased the new drugs available to patients and patients are getting a lot of benefit from it....So we're not saving anybody any money, were just making sure the money is well spent
The Chairman of the United Kingdom's National Institute for Health and Clinical Excellence, Sir Michael Rawlins, addressed the latest and most innovative technologies from the United Kingdom at the BIO 2010 International Convention in Chicago on May 4-5, 2010.